CClinicalTrials.gg
Not yet recruitingNCT07833150Updated Sep 22, 2026

Balance Performance and Quality of Life in Parkinson's Disease

An observational study in PARKINSON DISEASE (Disorder) and Health Adult Subjects, sponsored by Pamukkale University. Not yet recruiting. Open to participants aged 20 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by Pamukkale University · Observational

Study type
Observational
Model
Case-crossover
Time perspective
Cross-sectional
Enrollment
40
Ages
20 Years to 80 Years
Sex
All
01

Study summary

This observational study aims to examine the relationship between performance-based balance test results and quality of life in individuals with Parkinson's disease. It also seeks to determine which balance test best explains quality of life in this population.

Balance and functional performance will be assessed using the Six Spot Step Test, 30-Second Chair Stand Test, Timed Up and Go Test, Four Square Step Test, Berg Balance Scale, and 3-Meter Backward Walk Test. Quality of life will be evaluated using the 39-item Parkinson's Disease Questionnaire (PDQ-39). The findings may help clinicians select appropriate assessment methods and develop rehabilitation programs that address the factors associated with quality of life in individuals with Parkinson's disease.

02

Conditions studied

  • PARKINSON DISEASE (Disorder)
  • Health Adult Subjects

Browse trials for

Keywords

  • Parkinson Disease
  • Postural Balance
  • Quality of Life
  • Balance Assessment
  • Functional Performance
03

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will consist of individuals diagnosed with idiopathic Parkinson's disease who are followed at the Neurology Department of Pamukkale University Hospital and age- and sex-matched healthy individuals recruited from the same geographical region in Denizli, Türkiye.

Inclusion criteria

  • Willing to participate in the study and providing written informed consent
  • Having a diagnosis of idiopathic Parkinson's disease
  • Being 20 years of age or older
  • Being classified as stage 1-3 according to the Modified Hoehn and Yahr Scale
  • Being in the "on" medication state and undergoing assessment one hour after taking antiparkinsonian medication

Exclusion criteria

Exclusion Criteria:

  • Being a healthy individual matched for age and sex with a participant diagnosed with Parkinson's disease Willing to participate in the study and providing written informed consent Being 20 years of age or older
04

Study design

Observational model
Case-crossover
Time perspective
Cross-sectional
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • Parkinson's Disease Group

    Individuals diagnosed with Parkinson's disease who underwent assessments of balance, functional performance, fear of falling, disease severity, depressive symptoms, and quality of life. No intervention was administered as part of this observational study.

  • Healthy Control Group

    Age- and sex-matched healthy individuals without a diagnosis of Parkinson's disease who underwent balance and functional performance assessments. No intervention was administered as part of this observational study.

05

What researchers measure

Primary outcomes

  1. Health-Related Quality of Life Assessed by the PDQ-39

    Health-related quality of life in individuals with Parkinson's disease will be assessed using the 39-item Parkinson's Disease Questionnaire (PDQ-39). The PDQ-39 Summary Index ranges from 0 to 100, with higher scores indicating poorer health-related quality of life.

    Time frame: During the single assessment session (approximately 25 minutes)

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07833150
Lead sponsor
Pamukkale University
Responsible party
Büşra ÖZCAN (research assistant, Pamukkale University) — Principal investigator
First posted
Sep 22, 2026
Start date
Sep 17, 2026 (estimated)
Primary completion
Oct 10, 2026 (estimated)
Completion
Oct 10, 2026 (estimated)
Last update
Sep 22, 2026

Study contacts

Büşra ÖZCAN, MSc
Contact
busra6873@gmail.com
+905533514349
Borna FARHOOMAND, MSc
Contact
borna.farhoomand@gmail.com
+90544 903 36 38

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion